您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 总经理-上海创新中心
所属公司: 单永强博士
个人简介:
单永强博士,于中国医科大学获得临床医学学士和分子生物学硕士学位,于清华大学和北京协和医学院获得分子药理学博士学位,后于中国医学科学院进行博士后研究工作。单永强博士从事新药研发工作18年,积累了丰富的经验,在复杂疾病的疾病生物学和药理学领域有深厚的造诣。在加入复宏汉霖之前,单博士曾先后服务于国家人类基因组北方研究中心、北京大学分子医学研究所、诺华(中国)生物医学研究中心、华领医药、恒瑞医药,以及君圣泰生物等大型研究机构及企业,担任科学家、研究与早期开发部总监、靶点研究部负责人、转化科学副总裁/上海研发中心负责人等职务。 Dr. Yongqiang Shan got his B.Med. in Clinical Medicine and M.S. in Molecular Biology from China Medical University, and PhD. in Molecular Pharmacology from Tsinghua University & Peking Union Medical College. He then continued postdoctoral research in Chinese Academy of Medical Sciences.Dr. Shan has over 18 years of new drug research and development experience, with enormous knowledge in disease biology and pharmacology of complex diseases. Prior to joining Henlius, Dr. Shan has served as Scientist at CHGB, Institute of Molecular Medicine of Peking University and China Novartis Institute of Biomedical Research, as Director of Research and Early Development at Hua Medicine, as Head of Discovery Biology at Hengrui Pharmaceutical, and VP of Translational Science/Head of Shanghai R&D Center at HighTide Therapeutics.
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 副总裁
所属公司: 大橡科技有限公司
个人简介:
清华大学生物化学与分子生物学博士,师从我国分子酶学及蛋白结构领域专家王志新院士,主要致力于泛素-蛋白酶体通路关键分子的结构与功能研究。解博士在生物科技领域拥有超过15年的从业经验,曾在药渡、医渡云及神州医疗等企业任职。2020年加入大橡科技担任创新与战略合作副总裁,负责公司对外战略合作及商务拓展工作。Dr. Xie is VP of innovation and strategic partnerships at Daxiang Biotech, who holds a Ph.D. in Biochemistry and Molecular Biology from Tsinghua University, under the guidance of Dr. Zhixin Wang who is a leading expert in the field of molecular enzymology and protein structure in China. where he worked on Structural and functional studies of key molecules of the ubiquitin-proteasome pathway. Dr. Xie is an accomplished biotech veteran with over 15 years of corporate partnerships for biotech and pharmaceuticals companies. Prior to Daxiang Biotech, he held leadership roles at PHARMACODIA, YIDUCLOUD, and DC HEALTH.
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 执行总监、全球药物研发中国综合科学团队负责人
所属公司: 百时美施贵宝
个人简介:
边峰博士是百时美施贵宝全球药物研发中国综合科学团队执行总监, 常驻上海。她负责中国针对早期研发的外部合作,主要关注中国以及周边亚洲地区的创新性科学进展包括新靶点,突破性技术,新型有效或高度差异化的临床前分子和疗法,转化医学,并负责与生命科学领域建立密切的合作关系。之前她是辉瑞Emerging Science & Innovation (ES&I)高级总监/中国新兴科学与创新合作负责人。在加入辉瑞之前,边峰博士自2014年起在中国诺华生物医学研究中心担任高级研究员和肝脏疾病临床前药理学平台负责人。在诺华公司,她是项目负责人并管理肝病药理学平台,为中国和全球药物研发项目提供临床前药理数据。在诺华之前,她于2012年加入强生公司,是在上海参与建立生物研究实验室的关键科学家。在强生公司,她担任生物学副总监,参与管理CRO,学术研究合作以及内部研发项目。 边博士的研发生涯起始于美国Parke-Davis / Warner-Lambert公司,担任神经科学部门的临床前体内药理学家,后来成为辉瑞公司在美国的全球研发总部神经科学部门的首席科学家,为Lyrica®等项目做出贡献。她还参与阿尔茨海默病,抑郁症和皮肤纤维化等疾病的创新药物研究。边博士在小分子和生物药物研究方面拥有20多年的专业知识,她的工作支持多个创新药物项目进入人体实验阶段。边博士在俄亥俄州立大学获得生物化学博士学位,并在天津南开大学获得理学学士学位。Dr. Feng Bian is an Executive Director of Integrative Sciences/China R&D at Bristol Myers Squibb based in Shanghai. She is responsible for scouting and partnering in early R&D space to cultivate strong and in-depth scientific relationships with academic and life science communities with a primary focus on China and nearby regions to access emerging sciences including novel targets, breakthrough technologies, new or highly differentiated preclinical assets, and translation research.Before this, Dr. Bian was a Senior Director and China Emerging Science Lead in Pfizer Emerging Science & Innovation (ES&I) of Pfizer Worldwide Research, Development & Medical focusing on China and nearby Asia regions. Prior to Pfizer ES&I, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for worldwide drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principal scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has more than 20 years of expertise in small molecule and biologics drug discovery and her work has enabled several NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.
发布时间: 2022 - 03 - 11
点击次数: 0
所属职位: 首席运营官
所属公司: 再鼎医药全球研发
个人简介:
阎水忠博士于2015年9月加入再鼎医药,目前担任再鼎医药全球研发首席运营官。加入再鼎之前,阎水忠博士是科文斯公司早期研发上海研发中心负责人,全面负责公司在中国的相关业务。2009年至2012年期间,阎水忠博士是和记黄埔医药公司药物安全性评价和项目管理负责人。加入和记黄埔医药之前,阎水忠博士在美国辉瑞积累了丰富的经验。在其职业生涯中,阎水忠博士参与过多个候选药物的IND和NDA申请工作,积累起与数个国家的卫生注册机构合作的丰富经验。阎水忠博士拥有北京协和医科大学博士学位,并在美国芝加哥大学Ben-May癌症研究所完成博士后研究。阎水忠博士是美国毒理学会认证专家、中国毒理协会理事会理事、药物毒理与安全性评价专业委员会委员、中国药理学会药物毒理专业委员会委员及中国医药创新促进会药物研发专业委员会副主任委员。    James Yan, Ph.D., joined Zai Lab in September 2015 and currently serves as Chief Operating Officer, Global R&D.Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries.Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA).
74页次10/19首页上一页...  567891011121314...下一页尾页
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务